• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在临床实践中实施 Keytruda/Pembrolizumab 检测。

Implementing Keytruda/Pembrolizumab Testing in Clinical Practice.

机构信息

Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.

Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA

出版信息

Oncologist. 2018 Jun;23(6):647-649. doi: 10.1634/theoncologist.2017-0591. Epub 2018 Mar 9.

DOI:10.1634/theoncologist.2017-0591
PMID:29523645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6067935/
Abstract

This Commentary addresses the FDA approval of pembrolizumab and the changes necessary in clinical practice to identify patients who would benefit from such treatment.

摘要

本述评探讨了 pembrolizumab 获得 FDA 批准的情况，以及为了确定哪些患者将从这种治疗中获益，临床实践中需要做出的改变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a47/6067935/bdc16ca25412/onco12412-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a47/6067935/bdc16ca25412/onco12412-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a47/6067935/bdc16ca25412/onco12412-fig-0001.jpg

相似文献

1
Implementing Keytruda/Pembrolizumab Testing in Clinical Practice.在临床实践中实施 Keytruda/Pembrolizumab 检测。
Oncologist. 2018 Jun;23(6):647-649. doi: 10.1634/theoncologist.2017-0591. Epub 2018 Mar 9.
2
Pembrolizumab: first global approval.帕博利珠单抗：首个获得全球批准
Drugs. 2014 Oct;74(16):1973-1981. doi: 10.1007/s40265-014-0314-5.
3
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.基于生物标志物而非肿瘤类型获批的癌症药物——美国食品药品监督管理局批准帕博利珠单抗用于错配修复缺陷实体癌
JAMA Oncol. 2018 Feb 1;4(2):157-158. doi: 10.1001/jamaoncol.2017.4182.
4
In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.简而言之：帕博利珠单抗（可瑞达）用于治疗带有生物标志物的癌症。
Med Lett Drugs Ther. 2018 Jan 1;60(1537):e8.
5
Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.工程化肿瘤对免疫检查点疗法的超敏感性
Trends Cancer. 2017 Oct;3(10):675-677. doi: 10.1016/j.trecan.2017.08.002. Epub 2017 Sep 4.
6
Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.帕博利珠单抗（可瑞达）用于转移性非小细胞肺癌的一线治疗。
Med Lett Drugs Ther. 2017 Jan 30;59(1513):22-23.
7
FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.FDA 批准帕博利珠单抗用于卡介苗无应答性非肌层浸润性膀胱癌。
Oncology (Williston Park). 2020 Feb 20;34(2):44.
8
Keytruda UK's first early-access drug.可瑞达是英国首个早期准入药物。
Nat Biotechnol. 2015 May;33(5):437. doi: 10.1038/nbt0515-437a.
9
First Tissue-Agnostic Drug Approval Issued.首个组织非特异性药物获批。
Cancer Discov. 2017 Jul;7(7):656. doi: 10.1158/2159-8290.CD-NB2017-078. Epub 2017 Jun 5.
10
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗在含铂化疗期间或之后出现疾病进展的复发性或转移性头颈部鳞状细胞癌。
Oncologist. 2017 Jul;22(7):873-878. doi: 10.1634/theoncologist.2016-0496. Epub 2017 May 22.

引用本文的文献

1
New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review).免疫检查点抑制剂在癌症治疗中的作用机制及应用新进展（综述）。
Int J Oncol. 2023 Jul;63(1). doi: 10.3892/ijo.2023.5534. Epub 2023 Jun 16.
2
Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma.肝细胞癌中一种免疫相关预后预测指标的鉴定
Front Mol Biosci. 2020 Sep 24;7:567950. doi: 10.3389/fmolb.2020.567950. eCollection 2020.
3
Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes.

本文引用的文献

1
Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline Mutation.帕博利珠单抗治疗错配修复缺陷型子宫内膜癌伴胚系突变患者达到完全缓解
Oncologist. 2018 Jun;23(6):650-653. doi: 10.1634/theoncologist.2017-0526. Epub 2018 Feb 22.
2
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.免疫检查点阻断相关性免疫毒性的管理：一份合作立场文件。
Ann Oncol. 2016 Apr;27(4):559-74. doi: 10.1093/annonc/mdv623. Epub 2015 Dec 28.
3
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
无义抑制疗法：遗传性骨髓衰竭综合征治疗的新假说。
Int J Mol Sci. 2020 Jun 30;21(13):4672. doi: 10.3390/ijms21134672.
4
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.实体瘤免疫检查点免疫治疗的现有和新兴生物标志物。
Adv Ther. 2019 Oct;36(10):2638-2678. doi: 10.1007/s12325-019-01051-z. Epub 2019 Aug 13.
癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
4
PCR versus immunohistochemistry for microsatellite instability.用于微卫星不稳定性检测的聚合酶链反应（PCR）与免疫组织化学方法对比
J Mol Diagn. 2008 Mar;10(2):181-2; author reply 181. doi: 10.2353/jmoldx.2008.070147. Epub 2008 Feb 14.
5
Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary.日本和匈牙利高发病区胆囊癌中p53、K-ras的基因变化及微卫星不稳定性
World J Gastroenterol. 2008 Jan 7;14(1):70-5. doi: 10.3748/wjg.14.70.